Results 51 to 60 of about 9,015 (261)

Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Katy C. Norman, Richard T. George, Xue‐Qiao Zhao, Robert Pordy, Daniel Garcia, Wendy S. Putnam, Geetha Raghuveer, Brian W. McCrindle, Elena Fornari, Ivo Baric, Shubha Srinivasan, Melissa Diamond, Eliot A. Brinton, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +18 more
wiley   +1 more source

Patterns of Respiratory Symptoms and Asthma Diagnosis in School‐Age Children: Three Birth Cohorts

Allergy, EarlyView.
We performed guided multi‐domain clustering of symptoms and triggers in school‐age children across three birth cohorts. Using 15 variables, five clusters were identified. Two clusters showed a high prevalence of asthma with persistent symptoms.
Alex Cucco, Angela Simpson, Sadia Haider, Clare Murray, Stephen Turner, Paul Cullinan, Sarah Filippi, Sara Fontanella, Adnan Custovic, on behalf of STELAR/UNICORN Investigators, Raquel Granell, Graham Roberts, John W. Holloway, Syed Hasan Arshad, Ashley Woodcock, Graham Devereux   +15 more
wiley   +1 more source

Palivizumab nella profilassi del virus respiratorio sinciziale: analisi di impatto sul budget del SSN italiano

Farmeconomia: Health Economics and Therapeutic Pathways, 2011
Palivizumab is a monoclonal antibody to RSV that has been shown to significantly reduce the frequency of hospitalisations for RSV infection, in at-risk populations. However, payers are concerned about the budgetary impact of adopting palivizumab.
Daniela Roggeri
doaj   +1 more source

Respiratory syncytial virus immunization patterns in Germany, 2015-2020. [PDF]

Hum Vaccin Immunother
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children worldwide. Using routine statutory health insurance claims data including patients from all regions of Germany, we investigated
Wick M, Kliemt R, Poshtiban A, Kossack N, Diller GP, Soudani S, Bangert M, Kramer R, Damm O.   +8 more
europepmc   +2 more sources

Vaccination in dermatology 2025: Update considering current recommendations of the German Standing Committee on Vaccination

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The immunosuppressive and immunomodulatory treatment of dermatological patients necessitates the regular review and updating of standard vaccinations and vaccines indicated for specific conditions. The German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute regularly publishes evidence‐based vaccination recommendations ...
Johanna Stoevesandt, Marc Schmalzing, Sophia Mohme, Matthias Goebeler   +3 more
wiley   +1 more source

The Impact of Palivizumab for Respiratory Syncytial Virus Prophylaxis on Preschool Childhood Asthma. [PDF]

Vaccines (Basel)
Background: The respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and is associated with an increased risk of asthma development.
Hasson HO, Bachar Y, Hazan I, Golan-Tripto I, Goldbart A, Greenberg D, Hazan G.   +6 more
europepmc   +2 more sources

Respiratory syncytial virus preventives for children in Australia: current landscape and future directions

Medical Journal of Australia, EarlyView.
Summary Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infections, and a leading cause of hospitalisation in children under 6 months of age. Previously, palivizumab, a costly, short‐acting monoclonal antibody, was the primary preventive option.
Sam T Barnett, Jane Tuckerman, Ian G Barr, Nigel W Crawford, Danielle F Wurzel   +4 more
wiley   +1 more source

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease

Drug, Healthcare and Patient Safety, 2023
Shaun O’Hagan,1,2 Niamh Galway,3 Michael D Shields,3,4 Peter Mallett,1,4 Helen E Groves1,2 1Paediatric Infectious Diseases, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland; 2Wellcome-Wolfson Institute for Experimental Medicine, Queen ...
O'Hagan S, Galway N, Shields MD, Mallett P, Groves HE   +4 more
doaj  

Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged ≤5 years and its associated cost in Buenos Aires, Argentina [PDF]

, 2015
Background: Although information about the incidence of viral respiratory illnesses and their associated cost can help health officials explore the value of interventions, data are limited from middle-income countries.
Azziz Baumgartner, Eduardo, Carballal, Guadalupe, Durand, Lizette O., Echavarría, Marcela Silvia, Ekstrom, Jorge, Marcone, Débora Natalia, Vidaurreta, Santiago Manuel   +6 more
core   +1 more source

Evaluating the Impact of Different Methods on the Timing and Duration of RSV Epidemics: Analysis of Surveillance Data From the GERi (Global Epidemiology of RSV in Hospitalized and Community Care) Study

Influenza and Other Respiratory Viruses, Volume 19, Issue 6, June 2025.
ABSTRACT Background We previously reviewed methods for estimating the timing of respiratory syncytial virus (RSV) epidemics. This study examines the impact of various estimation methods on determining the start, end, duration, and capture rate of RSV epidemics.
Lisa Staadegaard, Marco Del Riccio, Susanne Heemskerk, Michel Dückers, Rodrigo A. Fasce, Patricia Bustos, Q. Sue Huang, Cheryl Cohen, Jocelyn Moyes, Vernon Jian Ming Lee, Li Wei Ang, Susana Monge, Isabel Martínez‐Pino, Mathieu Bangert, Rolf Kramer, John Paget, Foekje F. Stelma, Jojanneke van Summeren, Saverio Caini   +18 more
wiley   +1 more source